BJU international · 2026
Gleason pattern 4 length and active surveillance eligibility in Grade Group 2-4 prostate cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fletcher Sean A, Pickersgill Nicholas A, Aiken Nate, Assel Melissa J, Liso Nicole, Reuter Victor E, Ehdaie Behfar, Fine Samson W, Vickers Andrew J
Аннотация
OBJECTIVES: To evaluate whether total Gleason pattern 4 (GP4) length provides better risk stratification than current risk group criteria for determining potential active surveillance (AS) eligibility, using oncological outcomes after radical prostatectomy (RP).
PATIENTS AND METHODS: We identified patients with Grade Group (GG) 2-4 disease on magnetic resonance imaging (MRI)-targeted and systematic biopsy who underwent RP. We calculated total GP4 length as the summed millimetres of GP4 in systematic cores plus the average across MRI-targeted cores. Concordance analysis was used to evaluate how increasing GG corresponded to greater GP4 burden. We compared prediction of adverse pathology at RP and 5-year biochemical recurrence (BCR) between risk groups and total length of GP4.
RESULTS: Among 2499 patients, 1691, 694, and 114 had GG2, GG3, and GG4 disease, of whom 73%, 19%, and 15% had low amounts (<2 mm) of GP4. Patients with <2 mm of GP4, regardless of GG, had similar risks of adverse pathology (5.2% vs 5.0%) and 5-year BCR (20% vs 21%) as those with favourable intermediate-risk disease; if used as an AS threshold, <2 mm of GP4 would classify approximately twice as many patients as AS eligible, translating to ~50 000 men annually in the United States alone.
CONCLUSIONS: Total length of GP4 provides better risk stratification for AS eligibility than current favourable intermediate-risk group criteria. Further defining the optimal method for GP4 quantification and determining the appropriate cut-point is needed before clinical implementation.
PATIENTS AND METHODS: We identified patients with Grade Group (GG) 2-4 disease on magnetic resonance imaging (MRI)-targeted and systematic biopsy who underwent RP. We calculated total GP4 length as the summed millimetres of GP4 in systematic cores plus the average across MRI-targeted cores. Concordance analysis was used to evaluate how increasing GG corresponded to greater GP4 burden. We compared prediction of adverse pathology at RP and 5-year biochemical recurrence (BCR) between risk groups and total length of GP4.
RESULTS: Among 2499 patients, 1691, 694, and 114 had GG2, GG3, and GG4 disease, of whom 73%, 19%, and 15% had low amounts (<2 mm) of GP4. Patients with <2 mm of GP4, regardless of GG, had similar risks of adverse pathology (5.2% vs 5.0%) and 5-year BCR (20% vs 21%) as those with favourable intermediate-risk disease; if used as an AS threshold, <2 mm of GP4 would classify approximately twice as many patients as AS eligible, translating to ~50 000 men annually in the United States alone.
CONCLUSIONS: Total length of GP4 provides better risk stratification for AS eligibility than current favourable intermediate-risk group criteria. Further defining the optimal method for GP4 quantification and determining the appropriate cut-point is needed before clinical implementation.